Use of tramadol in early pregnancy and congenital malformation risk

30Citations
Citations of this article
69Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Only few studies exist regarding the risk of a teratogenic effect of tramadol when used in early pregnancy. Using the Swedish Medical Birth Register, women (deliveries in 1997-2013) who had reported the use of tramadol in early pregnancy were identified. Maternal characteristics and concomitant drug use were analyzed. Among 1,682,846 women (1,797,678 infants), 1751 (1776 infants) had used tramadol, 96 of the infants had a congenital malformation and 70 of them were relatively severe. The adjusted odds ratio for a relatively severe malformation was 1.33 (95% CI 1.05-1.70). The odds ratios for cardiovascular defects (1.56, 95% CI 1.04-2.29) and for pes equinovarus (3.63, 95% CI 1.61-6.89) were significantly increased. The study suggests a teratogenic effect of tramadol but the risk increase is moderate.

Cite

CITATION STYLE

APA

Källén, B., & Reis, M. (2015). Use of tramadol in early pregnancy and congenital malformation risk. Reproductive Toxicology, 58, 246–251. https://doi.org/10.1016/j.reprotox.2015.10.007

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free